St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer – A Brief Summary of the Consensus Discussion

The St. Gallen Consensus Conference on early breast cancer treatment 2023 was again a live event and took place in Vienna, Austria. After 4 years and one virtual event due to the pandemic, more than 2,800 participants from over 100 countries came together in Vienna, and the 2023 St. Gallen/Vienna conference was a great success. Over 3 days, the global faculty reviewed the most important evidence published during the last 2 years and debated over controversial topics, and finally, the consensus votes aimed to define the impact of the new data on everyday routine practice. Focuses of this year’s conference were radiotherapy and local management of the axilla, genetics, and their impact on treatment, as well as the role of the immune system and tumor-infiltrating lymphocytes in pathological reports and treatment decision-making. The traditional panel votes were moderated for the first time by Harold Burstein from Boston, and with questions previously voted on and live voting, the panel managed for the most part to clarify the critical questions. This report by editors of BREAST CARE summarizes the results of the 2023 international panel votes with respect to locoregional and systemic treatment as a brief news update but does not intend to replace the official St. Gallen Consensus publication that not just reports but also interprets the panel votes and will follow shortly in a major oncological journal. The next (19th) St. Gallen International Breast Cancer Conference will again take place in Vienna (save the date: March 12–15, 2025).

[1]  B. Bonanni,et al.  Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Cameron,et al.  Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. , 2023, The New England journal of medicine.

[3]  A. Jager,et al.  The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer , 2023, ESMO open.

[4]  R. Greil,et al.  Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer. , 2022, NEJM evidence.

[5]  F. Rodríguez‐Artalejo,et al.  Only virgin type of olive oil consumption reduces the risk of mortality. Results from a Mediterranean population-based cohort , 2022, European Journal of Clinical Nutrition.

[6]  M. Piccart,et al.  Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Shak,et al.  Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Loi,et al.  Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Kühn,et al.  Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy , 2022, Breast.

[10]  P. Fasching,et al.  Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[11]  M. Somerfield,et al.  Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Wapnir,et al.  Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for Lymphedema Prevention after Axillary Lymph Node Dissection—A Single Institution Experience and Feasibility of Technique , 2021, Journal of clinical medicine.

[13]  R. Greil,et al.  Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Gelber,et al.  Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy , 2021, Breast.

[15]  R. Greil,et al.  Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. , 2021, The New England journal of medicine.

[16]  E. Rutgers,et al.  Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Goetz,et al.  Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups , 2021, NPJ breast cancer.

[18]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Heil,et al.  Knowledge gaps in oncoplastic breast surgery. , 2020, The Lancet. Oncology.

[20]  E. Sawyer,et al.  Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial , 2020, The Lancet.

[21]  M. Gnant.  Challenges and Controversies in Breast Surgery , 2019, Breast Care.

[22]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[23]  W. Symmans,et al.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[24]  R. Gelber,et al.  Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[26]  R. Greil,et al.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[27]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[28]  F. Boccardo,et al.  LyMPHA and the Prevention of Lymphatic Injuries: A Rationale for Early Microsurgical Intervention , 2013, Journal of Reconstructive Microsurgery.

[29]  M. Gnant,et al.  Dual inhibition of HER2 in breast cancer treatment , 2012, The Lancet.

[30]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.